
CLAIMS


1. A compound of formula (I)



(I)

or prodrug thereof, or a pharmaceutically acceptable salt thereof.


2. A compound of formula (II)



(II)

or prodrug thereof, or a pharmaceutically acceptable salt thereof.


3. A compound of formula (IV)



(IV)

or a pharmaceutically acceptable salt thereof.


4. A compound of formula (V)



(V)

or a pharmaceutically acceptable salt thereof.

5. A compound as defined in claim 4 wherein the salt is a glycine salt of the formula



.

6. A glycine salt according to claim 5 wherein the salt is crystalline.

7. A glycine salt according to claim 5 or claim 6 wherein the salt is anhydrous.

8. An anhydrous crystalline glycine salt according to claim 7, characterized in that it provides an XRPD pattern substantially as set out in Table I

TABLE I XRPD Summay of Diffraction Angles and d-Spacing

Peak #	**Diff. Angle [°2θ]**	**d-spacing [Å]**
1	5.42	16.3027
2	5.78	15.2672
3	7.44	11.8749
4	9.59	9.2110
5	10.56	8.3679
6	10.81	8.1745
7	11.55	7.6557
8	13.04	6.7854

9	14.46	6.1218
10	14.84	5.9641
11	15.56	5.6903
12	16.25	5.4518
13	17.01	5.2072
14	18.32	4.8394
15	18.82	4.7116
16	19.00	4.6665
17	19.20	4.6182
18	19.60	4.5246
19	20.49	4.3310
20	20.99	4.2287
21	21.18	4.1924
22	21.54	4.1216
23	21.69	4.0934
24	22.34	3.9755
25	22.65	3.9233
26	23.20	3.8313
27	23.95	3.7127
28	24.42	3.6426
29	24.99	3.5610
30	25.17	3.5354
31	26.22	3.3958
32	26.54	3.3559

.

wherein the data in the table are plus or minus 0.2.

9. An anhydrous crystalline glycine salt according to claim 7, characterized in that it provides an XRPD pattern substantially in accordance with Figure 1.

10. A glycine salt according to claim 5 or claim 6 wherein the salt is a monohydrate.

11. A monohydrate crystalline glycine salt according to claim 10, characterized in that it provides an XRPD pattern substantially as set out in Table II

TABLE II XRPD Summary of Diffraction Angles and d-Spacing

Peak #	**Diff. Angle [°2θ]**	**d-spacing [Å]**
1	5.13	17.2011
2	5.75	15.3532
3	7.27	12.1458
4	9.28	9.5245
5	10.26	8.6117
6	10.61	8.3277
7	11.52	7.6772
8	12.87	6.8726
9	13.86	6.3858
10	14.56	6.0794
11	15.43	5.7389
12	16.31	5.4293
13	17.32	5.1171
14	18.52	4.7872
15	19.15	4.6299
16	19.89	4.4604
17	20.84	4.2586
18	21.23	4.1824
19	22.11	4.0168
20	22.55	3.9404
21	23.13	3.8421
22	23.83	3.7305
23	24.13	3.6847
24	25.47	3.4942
25	26.06	3.4171
26	27.91	3.1941
27	28.65	3.1137

28	29.05	3.0716
29	29.90	2.9860
30	30.42	2.9363
31	30.82	2.8990
32	31.34	2.8522
33	32.91	2.7196
34	33.38	2.6825
35	36.72	2.4456

wherein the data in the table are plus or minus 0.2.

12. A monohydrate crystalline glycine salt according to claim 10, characterized in that it provides an XRPD pattern substantially in accordance with Figure 4.

13. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

14. A compound as defined in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, for use in therapy.

15. A compound as defined in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease associated with DNMT1 activity.

16. Use of a compound as defined in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a disease associated with DNMT1 activity.

17. A method of treating a disease associated with DNMT1 activity comprising administering a compound as defined in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, to a human patient in need thereof.

18. A compound according to claim 15, use of a compound according to claim 16 or a method according to claim 17 wherein the disease associated with DNMT1 activity is cancer, a pre-cancerous syndrome, or a beta haemoglobinopathy disorder.

19. A compound, use of a compound or a method according to claim 18 wherein the cancer is myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), colorectal cancer (CRC),lymphoma (for example non-Hodgkin's lymphoma, melanoma, kidney, gastric, non-small cell lung cancer (NSCLC), or breast cancer.

20. A compound, use of a compound or a method according to claim 18 wherein the beta haemoglobinopathy disorder is sickle cell disease, sickle cell anemia, or beta thalassemia.

21. A combination comprising a compound as defined in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, and one or more other active agents.

22. A compound as defined in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, for use in the treatment of sickle cell disease, sickle cell anemia, or beta thalassemia.

23. A compound as defined in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, for use in the treatment of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), colorectal cancer (CRC), non-Hodgkin's lymphoma (NHL), melanoma, or breast cancer.